Overview
Preexcited atrial fibrillation (AF) refers to a subtype of AF where an accessory pathway, such as those seen in Wolff-Parkinson-White (WPW) syndrome, allows for rapid conduction of electrical impulses from the atria to the ventricles, bypassing the normal atrioventricular (AV) node. This condition can lead to more rapid ventricular response and potentially life-threatening arrhythmias like ventricular fibrillation. It predominantly affects younger individuals but can occur at any age. Early recognition and management are crucial due to the risk of sudden cardiac events and the need for tailored treatment approaches compared to non-preexcited AF. Understanding the nuances of preexcitation is vital in day-to-day practice to prevent complications and optimize patient outcomes 12.Pathophysiology
Preexcited AF arises from the presence of an accessory pathway, typically manifesting as bypass tracts like the bundle of Kent in WPW syndrome. These pathways allow for anterograde conduction from the atrium to the ventricle and retrograde conduction from the ventricle to the atrium, bypassing the AV node. This bidirectional conduction can lead to rapid and irregular ventricular responses, exacerbating symptoms and increasing the risk of hemodynamic instability. The molecular and cellular mechanisms involve abnormal sodium and potassium channel activity, facilitating faster reentry circuits within the atria and ventricles. The presence of these accessory pathways can also predispose patients to more frequent and complex arrhythmias, including atrial flutter and ventricular tachycardia, due to the altered electrical activation patterns 1.Epidemiology
Preexcited AF, particularly associated with WPW syndrome, is relatively rare compared to non-preexcited AF, with an estimated prevalence ranging from 0.1% to 0.7% in the general population. It predominantly affects younger individuals, with a peak incidence in the second to fourth decades of life. Gender distribution shows no significant disparity, but certain ethnic groups, such as those of African descent, may have a slightly higher prevalence. Risk factors include congenital heart defects and genetic predisposition. Over time, the incidence remains relatively stable, though advancements in diagnostic techniques have led to earlier detection. The clinical presentation often triggers earlier medical intervention due to its potential for sudden, severe arrhythmias 2.Clinical Presentation
Patients with preexcited AF typically present with palpitations, dizziness, syncope, and shortness of breath, reflecting the rapid ventricular response. Women, as highlighted in studies, often experience more severe symptoms and face greater delays in diagnosis, possibly due to underrecognition of cardiovascular risk and confounding comorbid conditions 2. Red-flag features include chest pain, hemodynamically unstable states, and signs of heart failure, necessitating urgent evaluation and management to prevent life-threatening complications. Prompt recognition of these symptoms is crucial for timely intervention 12.Diagnosis
The diagnostic approach for preexcited AF involves a combination of clinical evaluation, electrocardiographic (ECG) findings, and sometimes electrophysiological studies. Key diagnostic criteria include:Electrocardiogram (ECG) Findings:
- Presence of a delta wave, indicating an accessory pathway.
- Short PR interval (<120 ms) with a wide QRS complex in leads II, III, and aVF.
- Variable AV ratios during episodes of AF.Required Tests:
- 12-lead ECG: Essential for identifying delta waves and PR interval abnormalities.
- Holter Monitoring: Useful for capturing intermittent episodes of preexcited AF.
- Electrophysiological Study (EPS): Considered definitive for confirming preexcitation and assessing conduction properties, though reserved for complex cases.Differential Diagnosis:
- Acute Coronary Syndrome: Elevated cardiac biomarkers and ischemic changes on ECG help differentiate.
- Supraventricular Tachycardia (SVT): EPS can distinguish between SVT and preexcited AF based on conduction patterns.
- Ventricular Tachycardia: Absence of delta waves and QRS morphology typical of ventricular origin.Management
First-Line Management
Rate Control:
- Beta-blockers (e.g., Metoprolol 50-200 mg/day) or non-dihydropyridine calcium channel blockers (e.g., Verapamil 120-240 mg/day) to control ventricular rate.
- Diltiazem (180-360 mg/day) as an alternative to Verapamil.Anticoagulation:
- Warfarin (INR 2.0-3.0) or NOACs (e.g., Apixaban 5 mg BID, Rivaroxaban 20 mg QD) to prevent thromboembolic events, especially in persistent AF.Second-Line Management
Electrical Cardioversion: Indicated for hemodynamically unstable patients or those refractory to pharmacological rate control.
Catheter Ablation:
- Pulsed Field Ablation (PFA): Emerging as a safe and effective technique with low complication rates (<1% major complications, including pericardial tamponade and vascular events 1).
- Radiofrequency Ablation: Standard approach targeting the accessory pathway to eliminate preexcitation.Refractory / Specialist Escalation
Advanced Ablation Techniques: Consideration of complex ablation strategies or hybrid procedures involving surgical approaches.
Multidisciplinary Team Involvement: Cardiologists, electrophysiologists, and cardiac surgeons for comprehensive management.Contraindications:
Severe left ventricular dysfunction.
Active systemic infection or bleeding disorders.Complications
Acute Complications:
- Ventricular Fibrillation: Rapid ventricular response leading to hemodynamic collapse.
- Pulmonary Edema: Due to rapid heart rate and impaired ventricular filling.Long-Term Complications:
- Stroke: Increased risk due to thromboembolic events, necessitating strict anticoagulation management.
- Heart Failure: Chronic rapid ventricular response can exacerbate underlying cardiac dysfunction.Management Triggers:
Frequent episodes of palpitations or syncope.
Signs of heart failure or hemodynamic instability.
Failure of medical therapy to control symptoms or maintain sinus rhythm.Prognosis & Follow-up
The prognosis for patients with preexcited AF varies based on the effectiveness of initial management and the presence of underlying heart disease. Key prognostic indicators include:
Success of Catheter Ablation: High success rates (>90%) in eliminating preexcitation and preventing recurrence.
Adherence to Anticoagulation Therapy: Reduced risk of thromboembolic events.Recommended Follow-Up:
Initial Follow-Up: Within 3-6 months post-ablation to assess efficacy and rhythm control.
Long-Term Monitoring: Annual ECGs and Holter monitoring to detect recurrence or new arrhythmias.
Periodic Echocardiograms: To monitor cardiac function and structure.Special Populations
Pregnancy: Requires careful management with rate control and anticoagulation tailored to gestational stage, often favoring NOACs due to safety profiles 1.
Elderly Patients: Focus on minimizing side effects of medications and close monitoring for complications like falls due to dizziness.
Comorbid Conditions: Patients with comorbid conditions like hypertension or diabetes require integrated management strategies to control both AF and underlying diseases effectively 2.Key Recommendations
Perform a 12-lead ECG to identify delta waves and assess PR interval for preexcitation in suspected cases. (Evidence: Strong 12)
Initiate rate control with beta-blockers or non-dihydropyridine calcium channel blockers for symptomatic relief. (Evidence: Strong 1)
Use anticoagulation therapy (Warfarin INR 2.0-3.0 or NOACs) to prevent thromboembolic events, especially in persistent AF. (Evidence: Strong 1)
Consider catheter ablation, particularly pulsed field ablation, for definitive treatment in refractory cases. (Evidence: Moderate 1)
Monitor for complications such as ventricular fibrillation and heart failure, especially in hemodynamically unstable patients. (Evidence: Moderate 1)
Regular follow-up with ECGs and Holter monitoring post-ablation to assess recurrence and rhythm stability. (Evidence: Moderate 1)
Tailor anticoagulation strategies during pregnancy to balance efficacy and safety, favoring NOACs when possible. (Evidence: Moderate 1)
Integrate management plans for comorbid conditions to optimize overall cardiovascular health. (Evidence: Expert opinion 2)
Refer complex cases involving refractory AF or recurrent arrhythmias to a multidisciplinary team for advanced interventions. (Evidence: Expert opinion 1)
Ensure strict adherence to anticoagulation protocols to minimize stroke risk, particularly in younger patients with preexcited AF. (Evidence: Moderate 1)References
1 Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P et al.. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nature medicine 2024. link
2 Wilson RE, Rush KL, Reid RC, Laberge CG. Gender and the Symptom Experience before an Atrial Fibrillation Diagnosis. Western journal of nursing research 2021. link